Immix Biopharma, Inc. Annual Report - How They Did This Year

I’m putting together a plain-English guide to help you understand Immix Biopharma’s performance. My goal is to turn complex filing information into something that makes sense, helping you decide if this company fits your investment goals.

1. What does this company do?

Immix Biopharma is a clinical-stage company developing next-generation cell therapies. They do not yet sell products or generate revenue. Their main focus is NXC-201, a CAR-T cell therapy for relapsed AL Amyloidosis—a rare, fatal disease—and multiple myeloma. They use a proprietary platform called SMARxT to deliver drugs directly to disease sites, which aims to improve effectiveness while lowering side effects. They are currently running clinical trials to earn FDA approval.

2. Financial performance: The "Spending" Phase

Because they have no products on the market, Immix earns no revenue. The company operates at a loss, spending heavily on research and development. They spent $24.5 million on research and $8.2 million on general operations this year.

To stay afloat, the company relies on selling stock. In December 2025, they raised $100 million through a public stock offering, following a $9.3 million private sale in September. They ended the year with $112 million in cash. Management expects this to fund operations into 2027, depending on how fast they move through clinical trials.

3. Major wins and challenges

The company is navigating a high-stakes environment:

• Clinical Progress: Their lead drug, NXC-201, shows promise in the NEXICART-2 trial. Late 2025 data showed a 75% complete response rate in patients with AL Amyloidosis. Importantly, the therapy appears safe, with no reports of severe neurotoxicity, a common danger in these treatments.
• Regulatory Recognition: The FDA granted NXC-201 "Breakthrough Therapy" status for AL Amyloidosis. This allows for more frequent meetings with regulators and a faster review process, potentially speeding up the path to market.
• Funding Hurdles: The company is actively seeking non-dilutive funding, such as a pending $1.8 million grant from the California Institute for Regenerative Medicine, to supplement their current cash reserves.

4. Key risks for you

If you are considering an investment, keep these three risks in mind:

• Dilution: The company must sell stock to fund its work. The $100 million raised in December meant issuing more shares, which reduced the ownership percentage of existing investors. Future fundraising will likely do the same.
• The "All-or-Nothing" Trial Risk: Immix’s value depends almost entirely on the success of NXC-201. Clinical trials are unpredictable. Even with good early data, there is no guarantee the final trials will succeed. A failed trial could destroy most of the company’s value.
• Competition and Execution: The CAR-T market is crowded with major pharmaceutical companies. Immix must successfully scale its manufacturing to meet clinical and commercial standards. Any manufacturing delays or superior results from competitors could make NXC-201 less valuable.

---

Final Thought for Investors: Immix Biopharma is a classic "high-risk, high-reward" biotech play. Because they have no revenue, your investment is essentially a bet on the success of the NXC-201 clinical trials. If you are comfortable with the volatility inherent in early-stage drug development and the potential for future share dilution, the current clinical data and FDA status provide a clear window into their potential. If you prefer companies with established cash flow or lower clinical risk, this may be one to watch from the sidelines until they reach a major commercial milestone.